周五,BMO Capital Markets在诺和诺德公司(NYSE:NVO)公布Monlunabant肥胖症试验数据后,维持了其"跑赢大市"评级和160.00美元的股票目标价。这项2a期试验结果显示了令人鼓舞的减重效果,但也出现了一些精神方面的副作用。 试验显示,在16周时,经过安慰剂调整后的体重减轻了5.8%,超过了之前CB1受体拮抗剂在52周时的结果。尽管如此,报告显示出现了轻度至中度精神副 ...
近日,首都医科大学附属北京同仁医院的杨金奎教授团队在《Signal Transduction and Targeted Therapy》发表了题为“Potassium voltage-gated channel subfamily H member 2 (KCNH2) is a promising target for incretin secretagogue therapies”的封面研究论文 ...
BEIJING, Sept. 13 (Xinhua) -- China has always opposed the UK's so-called "six-monthly report" which makes irresponsible comments on Hong Kong affairs, a Chinese foreign ministry spokesperson said on ...
TMTPOST--"The prospects of AR industry are very promising," an AR industry entrepreneur told AsianFin, "With increased attention, and more mature technology, survival has become easier. However, we ar ...